- Home
- CBIO vs OPRT Comparison
CBIO vs OPRT Comparison
Compare CBIO & OPRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBIO
- OPRT
- Stock Information
- Founded
- CBIO 2003
- OPRT 2005
- Country
- CBIO United States
- OPRT United States
- Employees
- CBIO N/A
- OPRT N/A
- Industry
- CBIO
- OPRT Finance: Consumer Services
- Sector
- CBIO
- OPRT Finance
- Exchange
- CBIO Nasdaq
- OPRT Nasdaq
- Market Cap
- CBIO 308.0M
- OPRT 264.1M
- IPO Year
- CBIO N/A
- OPRT 2019
- Fundamental
- Price
- CBIO $14.29
- OPRT $6.61
- Analyst Decision
- CBIO Strong Buy
- OPRT Hold
- Analyst Count
- CBIO 5
- OPRT 2
- Target Price
- CBIO $25.60
- OPRT $8.00
- AVG Volume (30 Days)
- CBIO 98.3K
- OPRT 602.3K
- Earning Date
- CBIO 07-31-2025
- OPRT 08-06-2025
- Dividend Yield
- CBIO N/A
- OPRT N/A
- EPS Growth
- CBIO N/A
- OPRT N/A
- EPS
- CBIO N/A
- OPRT N/A
- Revenue
- CBIO N/A
- OPRT $724,757,000.00
- Revenue This Year
- CBIO N/A
- OPRT $27.48
- Revenue Next Year
- CBIO N/A
- OPRT $5.29
- P/E Ratio
- CBIO N/A
- OPRT N/A
- Revenue Growth
- CBIO N/A
- OPRT N/A
- 52 Week Low
- CBIO $10.83
- OPRT $2.37
- 52 Week High
- CBIO $21.40
- OPRT $9.25
- Technical
- Relative Strength Index (RSI)
- CBIO 52.92
- OPRT 58.35
- Support Level
- CBIO $13.50
- OPRT $5.51
- Resistance Level
- CBIO $16.00
- OPRT $6.67
- Average True Range (ATR)
- CBIO 0.79
- OPRT 0.28
- MACD
- CBIO 0.16
- OPRT 0.10
- Stochastic Oscillator
- CBIO 39.68
- OPRT 90.50
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
About OPRT Oportun Financial Corporation
Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.